SAN FRANCISCO, March 14, 2023 – Syapse®, a leading real-world evidence company dedicated to extinguishing the fear and burden of serious diseases by advancing real-world care, today announced two new studies focused on developing drug ontologies to support real-world evidence generation and the use of machine learning to predict time to diagnosis. Syapse will be presenting at the American Medical Informatics Association (AMIA) Informatics Summit being held March 13-16 in Seattle, WA.
"We are thrilled to present the results of our custom research at the AMIA Informatics Summit," said Vinod Subramanian, Chief Product, and Data Officer. "This study shows that AI-based tools can play a critical role in developing standards in RWE, in addition to early disease detection."
Unveiled at AMIA Informatics Summit, the Syapse studies include:
Subramanian added, "We are excited to continue our research and work with healthcare providers to further develop and refine our AI-based capabilities. We believe that they have the potential to revolutionize the way that healthcare is delivered, and we are committed to making this a reality."
In addition to presenting this research at AMIA, Syapse will be attending ISPOR, ASCO, and AACR. To learn more about Syapse research, and solutions, and connect with the team, click here.
Syapse is a company dedicated to extinguishing the fear and burden of oncology and other serious diseases by advancing real-world care. By marrying clinical expertise with smart technologies, we transform data into evidence—and then into experience—in collaboration with our network of partners, who are committed to improving patients’ lives through community health systems. Together, we connect comprehensive patient insights to our network, to empower our partners in driving real impact and improving access to high-quality care.